This document from Health GAP’s PEPFAR Watch is a community analysis of the success and challenges of PEPFAR’s Key Population program and recommendations for the next PEPFAR Ambassador.
Where Is PEPFAR’s Strategy for Key Populations?
Seven Global Civil Society Priorities for the 2021-2025 President’s Emergency Plan for AIDS Relief (PEPFAR) Strategy
As the largest funder of HIV/AIDS programming in the world, PEPFAR has the power and opportunity to move the dial. A large number of AVAC partners and other civil society organizations in Eastern and Southern Africa heard the call for comments and suggestions for the new strategy—and responded here with seven key priorities.
Tips to Approach Host Organization
A strong working relationship between a Fellow and Host Supervisor is instrumental to a successful fellowship. Fellows can be hosted by an employer or organization where they volunteer, or for an organization that aligns with project goals. This checklist supports applicants who are reaching out to prospective Host Organizations.
PEPFAR-Funded PrEP and VMMC Services in 14 Priority Countries
This infographic shows that PEPFAR’s increased investment and creation of a budget code resulted in improved scale-up of VMMC (VMMC). A budget code could have the same impact if applied to PrEP initiations.
BioPIC Adaptable Product Introduction Framework
This framework is intended to inform stakeholders involved in all stages of product introduction from clinical research to rollout in low- and middle-income countries (LMICs). While the framework focuses on activities to begin in parallel to phase III clinical trials, stakeholders in early product development phases may also want to understand what to expect in terms of downstream product introduction needs. Stakeholders involved in early product development may also consider leveraging some of the activities included to anticipate future needs.
Illustrated Glossary for Long-Acting Technologies
Language is important and how affected communities become familiarized with the technical aspects in emerging fields, such as nanomedicines to treat HIV, hepatitis C virus, TB and malaria, is an essential part of meaningful, equitable engagement in early stage science. The Illustrated Glossary for Long-Acting Technologies compiles frequent terms and concepts used in the research and development of long-acting technologies. The glossary is a non-exhaustive list and the graphics are artistic renderings meant to spur discussion and assist with community treatment literacy.
2021 Pipeline Report
The Treatment Action Group Pipeline Report provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV) and tuberculosis (TB).
Read the report on the Treatment Action Group website.
Calling on the Biden Administration to Scale Up mRNA Vaccine Manufacturing Capacity
This joint letter calls on the Biden Administration to rapidly scale up mRNA vaccine manufacturing capacity to reach approximately 4 billion people by the end of 2021.
Enhancing HIV Prevention with Injectable Preexposure Prophylaxis
Quarraisha Abdool Karim, Ph.D. writes about the results of HPTN 083 and the implications of long-acting injectable of PrEP with cabotegravir in the New England Journal of Medicine.
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
The results of HPTN 083, a trial evaluating the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW), in the New England Journal of Medicine.